Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Enrolling by invitation Phase 2

A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy

NCT07943598 · tracked via the Priya Life Science Japan tracker
Phase
Phase 2
Started
2026-12-16
Last updated
2026-11-17

Condition(s) studied

Duchenne Muscular DystrophyExon 44DMD

Investigational drug(s) / intervention(s)

Brogidirsen →

Brogidirsen: Brogidirsen will be administered for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until Brogidirsen is commercially available, whichever is earlier.

Study summary

This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.

Eligibility

Sex
MALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria 1. Participant has successfully completed Study NS-089/NCNP-02-201 2. Participant and parent(s) or legal guardian(s) are willing and able to comply with scheduled visits, investigational product (IP) administration plan, and study procedures 3. Participant must be on a stable dose of glucocorticoid (GC) steroids and is expected to remain on a stable dose of GC steroid treatment for the duration of the study 4. Other inclusion criteria may apply Exclusion Criteria: 1. Participant had an adverse event (AE) in Study NS-089/NCNP-02-201 that, in the judgment of the investigator and/or sponsor, precludes safe use of brogidirsen for the participant in this study 2. Participant had a treatment other than brogidirsen which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NS-089/NCNP-02-201 3. Participant is currently taking other investigational drug(s) 4. Participant is judged by the investigator to be inappropriate for this study for other reasons 5. Other exclusion criteria may apply

Primary outcome measure(s)

  • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) — Through study completion, an average of 124 weeks
  • Change in baseline in the following assessments: 12-lead electrocardiograms (ECGs), Vital signs, Physical and neurological examinations, Clinical laboratory tests — Through study completion, an average of 120 weeks

Trial sites (17)

FacilityCityRegionStatus
Children's Hospital Colorado Aurora Colorado
Cincinnati Children's Hospital Medical Center Cincinnati Ohio
Virginia Commonwealth University Health System Richmond Virginia
Queensland Children's Hospital South Brisbane Queensland
British Columbia Children's Hospital Vancouver British Columbia
London Health Sciences Centre London Ontario
Fukui Prefectural Hospital Fukui-shi Fukui
NHO Nagara Medical Center Nagara Gifu-shi, Gifu
NHO Osaka Toneyama Medical Center Toyonaka Osaka
Shiga General Hospital Moriyama-shi Shiga
National Center of Neurology and Psychiatry Kodaira Tokyo
Starship Children's Hospital Auckland New Zealand
Pusan National University Yangsan Hospital Yangsan Gyeongsangnam
Seoul National University Hospital Seoul South Korea
Ankara Bilkent City Hospital Ankara Turkey
Yeditepe University Kosuyolu Hospital Istanbul Turkey
S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital Izmir Turkey
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07943598 on ClinicalTrials.gov ↗ ← All trials in Japan